Science

Joaquin Mateo: Functional RAD51-IF to detect HRR defects in Prostate Cancer

Joaquin Mateo/axismeded.com

Feb 8, 2025, 06:58

Joaquin Mateo: Functional RAD51-IF to detect HRR defects in Prostate Cancer

Joaquin Mateo, Physician-Scientist at Vall d’Hebron Institute of Oncology, shared an article by Sara Arce-Gallego, et al. on X:

“Our latest paper is out in Cell Reports Medicine – Functional RAD51-IF to detect HRR defects in Prostate Cancer – exploring correlations between HRR mutations, HRD scores, and RAD51-IF in mPC biopsies.”

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence.

Authors: Sara Arce-Gallego, et al.

Joaquin Mateo: Functional RAD51-IF to detect HRR defects in Prostate Cancer

cancer Cell Reports Medicine fight against cancer Global fight against cancer HRR Joaquin Mateo mPC biopsies OncoDaily Oncology prostate cancer Sara Arce-Gallego Vall d’Hebron Institute of Oncology

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research

Stella Kyriakides joins ESO as Co-Chair and Senior Lecturer in Cancer Policy to Guide the 2026–2028 Strategic Plan

FDA Approves Nivolumab and Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer: CheckMate 8HW trial results